<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04935138</url>
  </required_header>
  <id_info>
    <org_study_id>CD20-011</org_study_id>
    <nct_id>NCT04935138</nct_id>
  </id_info>
  <brief_title>Cell-free DNA Analysis of Chromosome Anomalies in Early Pregnancy Loss</brief_title>
  <official_title>Cell-free DNA Analysis of Chromosome Anomalies in Early Pregnancy Loss</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Quest Diagnostics-Nichols Insitute</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Illumina, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Quest Diagnostics-Nichols Insitute</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study assesses the accuracy of cell-free DNA (cfDNA) analysis in detecting whole&#xD;
      chromosomal aneuploidies from maternal plasma of patients with early, missed miscarriage.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">June 1, 2021</start_date>
  <completion_date type="Anticipated">June 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>microarray analysis of products of conception (POC)</measure>
    <time_frame>7 days</time_frame>
    <description>chromosome anomalies</description>
  </primary_outcome>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Early Pregnancy Loss</condition>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>cfDNA analysis</intervention_name>
    <description>sequencing data from cfDNA analysis</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole Blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Previously pregnant women that have recently miscarried.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  5-20 weeks of gestation by ultrasound&#xD;
&#xD;
          -  Miscarriage diagnosed by ultrasound&#xD;
&#xD;
          -  Pregnancy tissue still present in utero, including an empty sac, and not completely&#xD;
             expelled&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Maternal age &lt; 18 years&#xD;
&#xD;
          -  No visible pregnancy tissue on ultrasound&#xD;
&#xD;
          -  Multiple fetal gestation (&gt; than singleton)&#xD;
&#xD;
          -  Pregnancy was conceived using in vitro fertilization (IVF) with preimplantation&#xD;
             genetic testing for aneuploidy (PGT-A) performed on the transferred embryo&#xD;
&#xD;
          -  No microarray testing is planned on the product of conception&#xD;
&#xD;
          -  Previous normal non-invasive prenatal testing (NIPT) or diagnostic testing (chorionic&#xD;
             villous sampling or amniocentesis) in the current pregnancy&#xD;
&#xD;
          -  Patient unable to provide consent&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Felicitas L Lacbawan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quest Diagnostics-Nichols Insitute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Quest Diagnostics</name>
      <address>
        <city>San Juan Capistrano</city>
        <state>California</state>
        <zip>92675</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Practice Committee of the American Society for Reproductive Medicine. Evaluation and treatment of recurrent pregnancy loss: a committee opinion. Fertil Steril. 2012 Nov;98(5):1103-11. doi: 10.1016/j.fertnstert.2012.06.048. Epub 2012 Jul 24.</citation>
    <PMID>22835448</PMID>
  </reference>
  <reference>
    <citation>Barisić I, Zergollern L, Muzinić D, Hitrec V. Risk estimates for balanced reciprocal translocation carriers--prenatal diagnosis experience. Clin Genet. 1996 Mar;49(3):145-51.</citation>
    <PMID>8737980</PMID>
  </reference>
  <reference>
    <citation>ESHRE. European Society of Human Reproduction and Embryology guideline: recurrent pregnancy loss. Human Reproduction Open 2018: 1-12.</citation>
  </reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 15, 2021</study_first_submitted>
  <study_first_submitted_qc>June 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 22, 2021</study_first_posted>
  <last_update_submitted>June 28, 2021</last_update_submitted>
  <last_update_submitted_qc>June 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abortion, Spontaneous</mesh_term>
    <mesh_term>Fetal Death</mesh_term>
    <mesh_term>Chromosome Disorders</mesh_term>
    <mesh_term>Chromosome Aberrations</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

